Article Text
Miscellanea
Cyclophosphamide in scleroderma lung disease
Statistics from Altmetric.com
OpenUrlCrossRefPubMedWeb of Science
Around 40% of patients with systemic sclerosis will develop significant interstitial lung disease. No agent has been proved in a randomised controlled trial to …